ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care

The combination of Astellas and Seagen's antibody-drug conjugate Padcev and Merck & Co's checkpoint inhibitor  Keytruda has shown improvements in survival not previously achieved in a broad population of patients with advanced urothelial carcinoma.